Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for XBiotech Inc. (XBIT : NSDQ)

• Company Description    XBiotech Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing True Human(TM) monoclonal antibodies for treating diseases. XBiotech Inc. is based in AUSTIN, United States. Number of Employees: 92

• Price / Volume Information    Yesterday's Closing Price: $3.18 Daily Weekly Monthly 20 Day Moving Average: 183,983 shares Shares Outstanding: 30.49 (millions) Market Capitalization: $96.95 (millions) Beta: 0.98 52 Week High: $8.32 52 Week Low: $2.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 11.19% 5.17% 12 Week 10.42% -7.37% Year To Date -19.49% -24.59%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5217 WINNEBAGO LANE - AUSTIN,TX 78744 USA ph: 512-386-2900 fax: 512-386-5505 swhitehurst@xbiotech.com http://www.xbiotech.com

• General Corporate Information    Officers John Simard - President and Chief Executive Officer Angela Hu - Principal Financial Officer and Principal Accounti W. Thorpe McKenzie - Director Jan-Paul Waldin - Director Peter Libby - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 98400H102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/11/25 Share - Related Items Shares Outstanding: 30.49 Most Recent Split Date: (:1) Beta: 0.98 Market Capitalization: $96.95 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.55 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -9.09% vs. Previous Quarter: -5.88% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -21.14 12/31/24 - -19.75 ROA 06/30/25 - - 03/31/25 - -19.55 12/31/24 - -18.08 Current Ratio 06/30/25 - - 03/31/25 - 29.15 12/31/24 - 11.56 Quick Ratio 06/30/25 - - 03/31/25 - 29.15 12/31/24 - 11.56 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 5.73 12/31/24 - 5.98 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©